[go: up one dir, main page]

MX2018001006A - Composicion farmaceutica que comprende un vector adenoviral. - Google Patents

Composicion farmaceutica que comprende un vector adenoviral.

Info

Publication number
MX2018001006A
MX2018001006A MX2018001006A MX2018001006A MX2018001006A MX 2018001006 A MX2018001006 A MX 2018001006A MX 2018001006 A MX2018001006 A MX 2018001006A MX 2018001006 A MX2018001006 A MX 2018001006A MX 2018001006 A MX2018001006 A MX 2018001006A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
adenoviral vector
formulation
dried composition
obtaining
Prior art date
Application number
MX2018001006A
Other languages
English (en)
Other versions
MX391216B (es
Inventor
Mathot Frédéric
BOURLES Erwan
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2018001006A publication Critical patent/MX2018001006A/es
Publication of MX391216B publication Critical patent/MX391216B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la formulación de vectores adenovirales en una mezcla acuosa o una composición liofilizada en presencia de azúcar amorfo y una concentración de sal baja, su formulación así como a un procedimiento de obtención de la composición seca.
MX2018001006A 2015-07-23 2016-07-20 Composicion farmaceutica que comprende un vector adenoviral. MX391216B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513010.7A GB201513010D0 (en) 2015-07-23 2015-07-23 Novel formulation
PCT/EP2016/067280 WO2017013169A1 (en) 2015-07-23 2016-07-20 Pharmaceutical composition comprising an adenoviral vector

Publications (2)

Publication Number Publication Date
MX2018001006A true MX2018001006A (es) 2018-06-06
MX391216B MX391216B (es) 2025-03-21

Family

ID=54106515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001006A MX391216B (es) 2015-07-23 2016-07-20 Composicion farmaceutica que comprende un vector adenoviral.

Country Status (11)

Country Link
US (1) US10722470B2 (es)
EP (1) EP3325016B1 (es)
JP (1) JP6797891B2 (es)
CN (1) CN108025081B (es)
AR (2) AR105401A1 (es)
BE (1) BE1023537B1 (es)
BR (1) BR112018001260A2 (es)
CA (1) CA2992922A1 (es)
GB (1) GB201513010D0 (es)
MX (1) MX391216B (es)
WO (1) WO2017013169A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11047534B2 (en) 2016-01-28 2021-06-29 EcoSense Lighting, Inc. Multizone mixing cup illumination system
BR112020007238A2 (pt) * 2017-10-16 2020-10-13 Glaxosmithkline Biologicals S.A. vetores adenovirais com replicação competente
WO2019113202A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
GB201721069D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
WO2019202083A1 (en) * 2018-04-20 2019-10-24 Laboratorio Reig Jofré, S.A. Stable adenovirus compositions
EP3587581A1 (en) * 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
MX2022009558A (es) * 2020-02-04 2022-09-09 Regeneron Pharma Contenido de humedad residual objetivo para farmaco liofilizado.
AU2021320395A1 (en) * 2020-08-07 2023-04-13 Janssen Biotech, Inc. Formulations for highly purified viral particles
US20230348935A1 (en) * 2020-09-24 2023-11-02 Nant Holdings Ip, Llc Vaccine compositions for mucosal immune response
KR20230113532A (ko) * 2020-10-23 2023-07-31 난트 홀딩스 아이피, 엘엘씨 점막 면역 반응을 위한 백신 조성물
CN116829134A (zh) * 2020-11-16 2023-09-29 生物技术欧洲股份公司 包含rna的lnp组合物及其制备、储存和使用方法
AU2021376893A1 (en) * 2020-11-16 2023-06-15 BioNTech SE Enhanced formulation stabilization and improved lyophilization processes
TW202237164A (zh) * 2020-12-04 2022-10-01 美商磨石生物公司 組合物及其使用方法
CN114903922B (zh) * 2021-02-09 2024-04-26 武汉博沃生物科技有限公司 包含腺病毒的医药配制品及其保存方法
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CN115554418B (zh) * 2022-11-22 2023-04-14 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP2163260B1 (en) * 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
RU2008118166A (ru) * 2005-11-22 2009-12-27 Вайет (Us) Составы, содержащие гибридные белки, включающие иммуноглобулин
CN1883707A (zh) 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
HUE033656T2 (en) 2010-03-31 2017-12-28 Stabilitech Ltd Binders for stabilizing virus particles
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
NZ628385A (en) 2012-03-12 2016-09-30 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
WO2015040234A1 (en) * 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation

Also Published As

Publication number Publication date
EP3325016C0 (en) 2023-12-20
BE1023537A1 (fr) 2017-04-26
BR112018001260A2 (pt) 2018-09-11
CN108025081B (zh) 2021-11-02
EP3325016A1 (en) 2018-05-30
US10722470B2 (en) 2020-07-28
AR121079A2 (es) 2022-04-13
GB201513010D0 (en) 2015-09-09
EP3325016B1 (en) 2023-12-20
AR105401A1 (es) 2017-09-27
US20180214379A1 (en) 2018-08-02
JP6797891B2 (ja) 2020-12-09
CN108025081A (zh) 2018-05-11
CA2992922A1 (en) 2017-01-26
MX391216B (es) 2025-03-21
BE1023537B1 (fr) 2017-04-26
WO2017013169A1 (en) 2017-01-26
JP2018521078A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
MX2018001006A (es) Composicion farmaceutica que comprende un vector adenoviral.
EA201790722A1 (ru) КОМПОЗИЦИЯ С НИЗКИМ pH, СОДЕРЖАЩАЯ КОНКРЕТНЫЕ КОНСЕРВАЦИОННЫЕ СИСТЕМЫ
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
MX389228B (es) Composiciones para tratar el cabello.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
CR20160499A (es) Composiciones estables de yodo no en complejo y métodos de uso
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
BR112017004925A2 (pt) composição e método
EA201791467A1 (ru) Водный офтальмологический раствор
MX391040B (es) Formulacion de alta concentracion.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
EA201891783A1 (ru) Композиция для растворения аморфных дитиазинов и способ ее применения
BR112017021527A2 (pt) dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
TR201906418T4 (tr) Solüsyonlarda 1-metilsiklopropenin stabilize edilmesine yönelik bileşimler ve yöntemler.
PL3164116T3 (pl) Kompozycje musujące zawierające kokryształy części kwasowej